Changfeng Pharmaceutical (02652) rose nearly 3% in the morning session. As of the time of writing, it was up 2.74%, trading at HKD 29.2, with a turnover of HKD 5.3645 million.
According to Zhitong Finance APP, Changfeng Pharmaceuticals (02652) rose nearly 3% in the morning session. As of the time of writing, it was up 2.74%, trading at HKD 29.2, with a turnover of HKD 5.3645 million.
In terms of developments, according to an official WeChat post by Changfeng Pharmaceuticals, the company recently successfully completed the first patient enrollment (FPI) for its self-developed bronchial valve lung volume reduction device. This marks the official start of the clinical validation phase, aiming to provide a minimally invasive interventional treatment option for patients with emphysema and other chronic obstructive pulmonary disease (COPD)-related conditions. The successful completion of the first enrollment surgery indicates that this innovative minimally invasive interventional device has officially entered the clinical validation stage.
It is reported that patients with emphysema often experience dynamic hyperinflation and restricted mobility. Existing therapies face significant unmet clinical needs in achieving long-term management and substantially improving quality of life. The device used in this human trial leverages bronchoscopic airway-level airflow regulation and targeted lung volume reduction strategies, aiming to reduce residual volume (RV) while improving lung function and exercise tolerance. It also seeks to enhance reproducibility and postoperative management controllability based on individualized assessments.
This study will proceed as planned with continuous patient enrollment, perioperative safety monitoring, and multidimensional assessments involving imaging and pulmonary function tests. Key metrics will cover device and procedure-related safety, technical success rates, and trends in critical clinical outcomes such as FEV1, RV, 6MWD, and SGRQ. The study data will form an auditable evidence chain to support subsequent registration strategies and commercialization decisions.
